GCP: Investigator Responsibilities I & II

Comprehensive practice flashcards covering investigator qualifications, site agreements, protocol compliance, safety reporting, oversight, delegation, and ethical responsibilities from GCP Investigator Responsibilities I and II.

Who are the key clinical trial stakeholders situated at the trial site?

The Principal Investigator (PI), Co-Investigator (Co-I), Clinical Research Coordinator (CRC), and the study team (such as the research pharmacist, nurse, and technician).

Which stakeholder at the trial site serves as the main communication point to the Ethics Committee (EC) or Institutional Review Board (IRB)?

The trial site (specifically the Principal Investigator and study team).

Who are the clinical trial stakeholders representing the sponsor?

The pharmaceutical company or contract research organization (CRO), Clinical Research Associate (CRA), Clinical Trials Assistant / executive (CTA), Biostatistician, and the sponsor study team (scientific officer, pharmacovigilance, data management, central lab).

Which clinical trial stakeholder serves as the main communication point to the Health Sciences Authority (HSA)?

The sponsor.

Which bodies represent the regulatory authorities and oversight committees in clinical trials?

Ethics Committees (EC) / Institutional Review Boards (IRB) and Regulatory Authorities (such as the HSA, FDA, and EMA).

What do the professional abbreviations CRA and CTA stand for in clinical trial operations?

CRA stands for Clinical Research Associate, and CTA stands for Clinical Trials Assistant / executive.

According to ICH GCP 4.1.1, how must an investigator be qualified to assume responsibility for a trial?

By education, training, and experience to assume responsibility for the proper conduct of the trial.

What document must the investigator provide as evidence of their qualifications?

An up-to-date curriculum vitae (CV) and/or other relevant documentation requested by the sponsor, EC, or regulatory authority.

Which regulatory and ethical standards must an investigator be aware of and comply with?

Good Clinical Practice (GCP) and applicable regulatory requirements.

From which sources must an investigator become thoroughly familiar with the appropriate use of an investigational product (IP)?

The protocol, the current Investigator's Brochure (pre-marketed drug) OR SIB (marketed drug), the product information, and other information sources provided by the sponsor.

What was the grant amount awarded to the investigator in 2006 under the NUS Academic Research Fund in the sample CV?

$\$89{,}247$ for "Statistical methods for genome-wide quantitative trait loci (QTL) mapping."

How should an investigator demonstrate potential for recruiting trial participants?

By demonstrating (e.g., based on retrospective data) a potential for recruiting the required number of suitable trial participants within the agreed recruitment period.

What time commitment requirement is placed upon the investigator under GCP?

Having sufficient time to properly conduct and complete the trial within the agreed trial period.

What resource requirements concerning staff and facilities must an investigator maintain?

An adequate number of qualified staff and adequate facilities for the foreseen duration of the trial to conduct it properly and safely.

What must an investigator ensure regarding all persons assisting with the trial?

That they are adequately informed about the protocol, the investigational product(s), and their assigned trial activities.

What standard governs trial-related training provided by an investigator to assisting staff?

The training should correspond to what is necessary to enable them to fulfill their delegated trial activities that go beyond their usual training and experience.

What must the investigator or institution do when retaining external individuals or parties for trial-related duties?

Ensure the individual or party is qualified to perform those duties and implement procedures to ensure the integrity of the functions performed and data generated.

What delegation documentation must the investigator maintain at the trial site?

A site delegation list of appropriately qualified persons to whom the investigator has delegated significant trial-related duties.

Which quality assurance and regulatory oversight activities must the investigator permit at the site?

Monitoring and auditing by the sponsor, and inspections by the Ethics Committee (EC) and Regulatory Authority (RA).

What approvals must the investigator or institution possess before initiating a clinical trial?

Written and dated approval from the Regulatory Authority (RA) and Ethics Committee (EC) for the protocol, informed consent form, consent updates, participant recruitment procedures, and any other written information provided to participants.

What product documentation must the investigator submit as part of the written application to the EC?

A current copy of the Investigator's Brochure (IB) or product information brochure (PIB).

What action must an investigator take if the Investigator's Brochure (IB) or PIB is updated during the trial?

Supply a copy of the updated IB or PIB to the Ethics Committee (EC) and Regulatory Authority (RA).

What information must the investigator provide to the RA and EC during the conduct of the trial?

Updates to participant information (e.g., revised informed consent documents), summaries of trial status, and any changes significantly affecting trial conduct or increasing risk to participants.

How does an investigator confirm agreement with the sponsor prior to study execution?

By signing the protocol, or an alternative contract, to confirm agreement with the sponsor and agree to comply with the protocol, GCP, and applicable regulations.

What are the investigator's responsibilities concerning protocol deviations (PDs)?

Document all deviations (including those identified by the sponsor during monitoring), review and explain them, and implement appropriate measures to prevent recurrence.

Under what circumstance may an investigator deviate from the protocol without prior approval?

Only where necessary to eliminate an immediate hazard or hazards to trial participants.

What must an investigator do after deviating from the protocol to eliminate an immediate hazard?

Inform the sponsor promptly and report information regarding the immediate hazard, the implemented change, and the subsequent proposed protocol amendment to the IRB/RA.

If a clinical trial is prematurely terminated or suspended for any reason, what are the investigator's duties to participants?

Promptly inform the trial participants and ensure appropriate therapy and follow-up for them.

Who must be promptly informed if a trial is prematurely terminated or suspended by the investigator or sponsor?

The institution, the IRB/IEC, and the regulatory authorities, accompanied by a detailed explanation of the reasons.

Whom must the investigator inform if a trial is prematurely terminated or suspended by the IRB?

The institution and the sponsor.

Can an IRB suspend or terminate a clinical trial for both favourable and unfavourable reasons?

Yes, an IRB may prematurely terminate or suspend a trial for favourable or unfavourable reasons.

Who may hold responsibility for trial-related medical care and clinical decisions at the site?

A qualified physician, qualified dentist, or qualified healthcare professional (registered in accordance with local regulatory requirements) serving as PI or Co-I.

What are the investigator's medical care obligations regarding adverse events?

Ensure that adequate medical care is provided to a trial participant for any adverse events, including clinically significant laboratory values, related to the trial.

What should the investigator do if they become aware of an intercurrent illness in a trial participant?

Inform the trial participant when medical care is needed for intercurrent illness(es) of which the investigator becomes aware.

What level of access must an investigator provide if a study drug has potentially fatal toxicity?

The investigator should be readily available by phone or other electronic communication $24\text{ hours}$ a day and in reasonably close proximity to study trial participants.

How must trial participants be informed about obtaining medical contact with the investigator?

They must be clearly educated on the possible need for contact and provided with phone numbers, e-mail addresses, and other contact information in writing.

What must an investigator arrange regarding participant medical care during periods of personal unavailability?

Delegate responsibility for medical care to a specific qualified physician who will be readily available to trial participants during that time.

Under what condition is it recommended to involve the trial participant's primary physician?

With the agreement of the trial participant.

In an emergency, who is authorized to treat a trial participant if the investigator is absent?

Any doctor may, in the absence of the investigator or their assistance, treat a trial participant if it is in the interest of the participant.

How must critical adverse events or laboratory abnormalities be reported to the sponsor?

According to the reporting requirements and within the time periods specified by the sponsor in the protocol.

Are unfavourable medical events occurring during screening before investigational product administration reportable?

Yes, they should be considered and reported to the sponsor if required by the protocol.

What is the reporting timeline for Serious Adverse Events (SAEs) to the sponsor?

All SAEs must be reported immediately to the sponsor, except for those identified in the protocol or Investigator's Brochure as not needing immediate reporting.

What must follow an immediate report of a Serious Adverse Event (SAE)?

Detailed, written reports provided promptly.

What additional information must an investigator supply to the sponsor and IRB/IEC in the case of a reported death?

Any additional requested information, such as autopsy reports and terminal medical reports or any protocol deviations that occurred that could have contributed to the death.

Who retains responsibility when safety reporting activities are delegated to site staff?

The investigator retains overall responsibility for participant safety and compliance with reporting requirements.

To whom may an investigator delegate study-related tasks during a clinical investigation?

Employees, colleagues, or other third parties (individuals or entities not under direct supervision, who may be identified with sponsor support).

Who is held accountable for regulatory violations resulting from inadequate supervision of delegated tasks?

The investigator.

What is the first major area evaluated by the FDA when assessing the adequacy of an investigator's supervision?

Whether individuals who were delegated tasks were qualified to perform such tasks.

What is the second major area evaluated by the FDA when assessing an investigator's supervision?

Whether study staff received adequate training on how to conduct delegated tasks and were provided with an adequate understanding of the study.

What is the third major area evaluated by the FDA when assessing an investigator's supervision?

Whether there was adequate supervision and involvement in the ongoing conduct of the study.

What is the fourth major area evaluated by the FDA when assessing an investigator's supervision?

Whether there was adequate supervision or oversight of any third parties involved in the study to the extent reasonably possible.

What qualifications must an individual have before an investigator delegates a task to them?

They must be qualified by education, training, and experience to perform the delegated task.

What prerequisites do most clinical or medical trial tasks require?

Formal medical training, as well as applicable licensing or certification requirements.

Who must be responsible in all cases for trial-related medical or dental decisions and care?

A qualified physician (or dentist).

Which screening activities have been cited in FDA inspections as being inappropriately delegated?

Screening evaluations, including obtaining medical histories and assessing inclusion/exclusion criteria.

Which clinical assessment activities have been cited in FDA inspections as inappropriately delegated?

Physical examinations, evaluation of adverse events, and assessments of primary study endpoints.

Which regulatory participant-interaction process has been cited in FDA inspections as inappropriately delegated?

Obtaining informed consent.

What must be done if a protocol specifies higher qualifications for a task than local law permits?

The protocol must be followed even if local law permits individuals with different qualifications to perform the task (e.g., if a protocol specifies a physician must perform physical exams, a nurse cannot perform them).

What three elements must an investigator record on the list of delegated persons?

Describe the delegated tasks, identify the qualifying training (e.g., referring to a CV on file), and identify the dates of study involvement.

Must an investigator maintain a single combined delegation list or separate lists for multiple trials?

The investigator should maintain separate lists for each study conducted.

Under what condition might formal delegation documentation not be required for trial activities?

In situations where the activities are performed as part of routine clinical practice.

What must be documented regarding external service providers retained by the investigator or institution?

Agreements made by the investigator/institution with service providers for trial-related activities must be documented.

Which trial personnel must receive adequate training, and when?

All staff, including new staff hired after the study has already begun.

What aspects of the study must site staff understand to be considered adequately trained?

The purpose of the study, the protocol details, attributes of the investigational product, regulatory requirements, acceptable trial standards, participant protection standards, and any relevant trial changes.

What is the investigator's duty if trial training is provided directly by the sponsor?

Ensure that the staff receive the sponsor's training or any information related to their role in the study.

In a clinical study with multiple investigators, who holds the primary supervisory role?

The Principal Investigator (PI).

Can a sub-investigator be delegated the primary supervisory role for the clinical site?

No, a sub-investigator should not be delegated the primary supervisory role for the site.

What staff-related factors can impair an investigator's ability to provide adequate supervision?

Inexperienced study staff and a demanding workload for study staff.

What protocol and patient-related factors can challenge an investigator's supervisory capacity?

Complex clinical trials (many observations, large data volume), a large number of enrolled participants, and a seriously ill participant population.

What site structure factors challenge an investigator's ability to supervise a study adequately?

Conducting multiple studies concurrently, conducting a study from a remote (off-site) location, or conducting a study across multiple sites not in close proximity.

What regular meetings should be incorporated into an investigator's trial oversight plan?

Routine meetings with staff (to review progress, AEs, and protocol updates) and routine meetings with the sponsor's monitors (CRAs).

What quality-control procedures must be detailed in an investigator's oversight plan?

Procedures for timely correction and documentation of problems identified by study staff, monitors, or auditors, and procedures for reviewing the performance of delegated tasks.

What procedure must an investigator establish regarding informed consent oversight?

A procedure for ensuring that the consent process follows ethical principles and that participants understand the nature and risks of participation.

What standards must an investigator's data procedure enforce regarding source data?

A procedure for ensuring that source data are accurate, contemporaneous, and original.

What procedure must an investigator maintain regarding Case Report Forms (CRFs)?

A procedure for ensuring that information in source documents is accurately captured on the CRFs.

What process must an investigator's oversight plan have for handling monitor-identified discrepancies?

A procedure for dealing with data queries and discrepancies identified by the study monitor.

What responsibilities does an investigator have when working with staff provided by a Site Management Organization (SMO)?

Ensure that the SMO staff are qualified to perform delegated tasks, have received adequate training on those tasks and the study, and determine whether the investigator needs to provide training.

Who shares responsibility for the quality of work performed by an SMO at a site?

The sponsor who retains the SMO.

What actions should an investigator take when observing poor performance by site staff?

Document observed deficiencies in writing to the staff member's supervisor(s) and inform the sponsor.

What may need to happen to a clinical trial if staff performance deficiencies are severe?

The clinical trial may need to be voluntarily suspended until personnel can be replaced.

Who is responsible for ensuring the competence of independent central facilities (e.g., central labs, ECG, radiology)?

The sponsor is responsible for ensuring these parties are competent to fulfill and are fulfilling their study responsibilities.

How can a protocol violation be legally construed as a failure to protect participant safety?

When failure to comply with the protocol exposes participants to unreasonable risks, such as failing to perform mandatory safety laboratory tests (e.g., CBC for an oncology drug that causes neutropenia).

What is the GCP rule regarding financial conflicts of interest for investigators and trial personnel?

The investigator, any person assisting them, or any trial participant shall not directly or indirectly have any financial interest in the trial.

Under FDA 21 CFR 54.4 financial disclosure rules, what equity interest threshold requires reporting?

Any equity interest in a pharmaceutical company that exceeds $\$50{,}000$ in value.

Under FDA 21 CFR 54.4, what threshold for significant payments of other sorts requires disclosure?

Payments totaling $\$25{,}000$ or more from any single pharmaceutical company (such as research grants, equipment, retainers, or honoraria).

Is a trial participant obligated to give a reason when prematurely withdrawing from a trial?

No, the participant is not obliged to provide a reason for withdrawing prematurely.

What should the investigator do when a participant decides to withdraw prematurely?

Make a reasonable effort to ascertain the reason(s), while fully respecting the participant's rights and ensuring no interference with their decision.

What post-trial information should the investigator provide to participants once unblinded by the sponsor?

Inform the participant about the trial results and the specific treatment received.

What are the investigator's core duties regarding the trial's randomisation procedures?

Follow the trial's randomisation procedures and ensure the treatment randomisation code is broken only in accordance with the protocol.

What must an investigator do if emergency premature unblinding of an investigational product is required?

Perform unblinding without undue delay to protect safety, and promptly document and explain to the sponsor the reason for unblinding (e.g., accidental or emergency due to an SAE).

What participant identification record must an investigator maintain at the trial site?

A trial participant identification log containing the names and particulars of every person participating in the trial.

What rules govern making changes or corrections to Case Report Forms (CRFs)?

Any change or correction should be dated, initialed, explained (e.g., via an audit trail), and should not obscure the original entry.

What should be defined regarding source records prior to starting the trial?

Define what is considered to be a source record, identify the methods of data capture, establish their location, and avoid unnecessary transcription steps.

How frequently must an investigator submit written progress reports to the Regulatory Authority and Ethics Committee?

Annually, or more frequently if requested by the RA and/or EC.

Within what time frame must the investigator submit the final report upon completion of a clinical trial?

Provide a summary of the trial outcome to the RA and EC, and submit the final report within $3\text{ months}$ of completion to the EC, RA, and Sponsor.